

Anti-TNFRSF5/CD40 Antibody (Mitazalimab)

Introduction

Mitazalimab (ADC-1013; JNJ-64457107) is an FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, such as dendritic cells (DCs), to prime tumor-reactive T cells. As a result, Mitazalimab induces tumor-specific T cell infiltration and tumor killing. Mitazalimab reshapes the tumor-infiltrating bone marrow microenvironment.

Product parameters

Alternative Names	ADC 1013, JNJ-64457107
Target Accession	P25942
Target	TNFRSF5 / CD40
CAS number	2055640-86-1
Molecular Weight	143.44 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

